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What is already known about this topic? 
 Current pemphigus vulgaris (PV) disease activity indices include the recently 
validated Pemphigus Disease Area Index (PDAI) and the Autoimmune 
Bullous Skin Disorder Intensity Score (ABSIS).  
 The Oral Disease Severity Score (ODSS) has been demonstrated to have good 
inter- and intra-observer reliability in both lichen planus (LP) and mucous 
membrane pemphigoid (MMP). 
 
What does this study add? 
 The ODSS is shown to be a thorough, sensitive, yet quick assessment tool for 
oral involvement in PV.  
 Its versatility for use additionally in MMP and LP is an added advantage over 
previously validated methods. 
 
SUMMARY 
Objectives 
The primary aim of this study was to validate the Oral Disease Severity Score 
(ODSS) for the assessment of oral involvement in pemphigus vulgaris (PV). A 
secondary aim was to compare the inter – intra- observer variability and ease of use 
with the Physician’s Global Assessment (PGA) and the oral scoring methods used in 
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and the Pemphigus 
Disease Area Index (PDAI). 
 
Methods 
15 patients with mild to moderately severe oral PV were scored for disease severity 
by 10 oral medicine clinicians using the ODSS, PGA and the oral sections of ABSIS 
and PDAI. Two clinicians re-scored all patients after a minimum two-hour interval. 
 
Results 
Inter-observer reliability was assessed using an intra-class correlation coefficient 
(ICC). For the ODSS total score the ICC was 0.83, PDAI (oral total activity) 0.79 
ABSIS (oral total) 0.71 and PGA was 0.7. Intra-observer agreement between initial 
scoring and re-scoring of the same subject by two clinicians demonstrated an ICC for 
each of 0.97 and 0.96 for ODSS total score; 0.99 and 0.82 for the PDAI oral activity; 
0.86 and 0.45 for the ABSIS total and 0.99 and 0.64 for the PGA. Convergent validity 
was good with a correlation coefficient of greater than 0.5 (p<0.0001). The mean time 
(SD) (seconds) taken to complete each scoring method was: ODSS 76±37; PDAI 
117±16; ABSIS 75±19.  
 
Conclusion 
This study has validated the ODSS for the assessment of oral PV. It has shown 
superior inter- and intra-observer reliability to PDAI, ABSIS and PGA and is quick to 
perform. 
 
INTRODUCTION 
Pemphigus vulgaris (PV) is a rare autoimmune bullous disease, which can present 
with or develop into a condition with severe and recalcitrant oral mucosal lesions.1 
Optimal management of such cases relies upon careful clinical assessment and 
documentation without which there may be a delay in the recognition of therapeutic 
response or of treatment failure.  
 
To determine the optimal management for PV, numerous clinical trials have been 
undertaken. However, assessment of efficacy has been hampered by the lack of 
validated clinical outcome measures particularly where mucosal sites have been 
affected. A Cochrane review revealed that over 116 outcome measures have been 
described in 96 articles and concluded that there was insufficient evidence to 
determine which therapy is optimal.2 Since that time there have been further 
systematic reviews, which similarly have been unable to clearly establish optimal 
therapeutic guidelines.1, 3 Multiple PV disease activity indices including the 
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease 
Area Index (PDAI) have been validated.4, 5, 6 While these methodologies include 
mucosal scores, our aim was to compare their sensitivity to a more detailed 
methodology for scoring oral mucosal sites. Given the recalcitrant nature of oral 
lesions in severe PV it  is imperative that a formally validated, sensitive and user 
friendly scoring methodology for the oral mucosa be available to facilitate 
international collaboration, multicentre studies as well as providing more useful 
comparison of clinical outcomes in smaller case series. Thereafter, sequential scores 
over time relating disease activity with other outcome measures including quality of 
life measures and desmoglein antibody titres will be most informative. 
 
The Oral Disease Severity Score (ODSS) is a comprehensive scoring methodology 
devised by the Oral Medicine group at Guy’s Hospital as part of a strategy of having 
disease severity scores applicable to most, if not all, oral mucosal diseases. It was first 
developed from a scoring system devised for multi-site mucous membrane 
pemphigoid (MMP).7 The ODSS records the presence of lesions and degree of 
activity at multiple oral sites. Additionally it includes a subjective assessment of the 
patient’s degree of oral pain over the preceding week. Previous studies have 
demonstrated that the ODSS has good inter- and intra-observer reliability in both 
lichen planus (LP) and MMP.8, 9 In addition it has been shown to be valuable in the 
assessment of therapeutic response over time in severe mucosal LP and PV.10, 11 
 
The primary aim of this study was to validate the ODSS for the assessment of oral 
involvement in PV. We invited oral medicine clinicians from four centres in the UK 
with a range of experience in scoring methodologies and included patients with a 
range of disease severity of oral pemphigus.  In the validation of the ODSS we 
investigated the inter- and intra-observer variability and ease of use. The ODSS was 
used in parallel with the PGA and the oral part of two recently proposed and validated 
systems for autoimmune bullous diseases, the ABSIS and PDAI. We additionally 
sought to assess convergent validity between PDAI and ODSS, ABSIS and PGA .4, 5, 
6, 12  
 
METHODS 
Research ethics approval was obtained (REC15/ES/0038). The study was performed 
within the Oral Medicine department at Guy’s Hospital, London. Ten oral medicine 
clinicians from four UK Oral Medicine centres were involved. Fifteen patients were 
scored using the ODSS in addition to the oral sections of the ABSIS, the PDAI and 
PGA. Patients were scored during the course of one day. Each patient remained in one 
room with an assistant who recorded the scores and timed each methodology. 
Clinicians rotated until all patients had been scored. Two clinicians re-scored all 
patients after a minimum two-hour interval in order to reduce recall (see statistical 
methods below). Twelve sets of scores were recorded for each patient.  
 
Physicians 
Clinicians participating in the study were either Consultants in Oral Medicine (n=8) 
or Oral Medicine trainees (n=2). 6 clinicians were both medically and dentally 
qualified with one additionally a practicing dermatologist, while the remaining 4 
clinicians were dentally qualified alone. 5 clinicians routinely used the ODSS in 
clinical practice while the remaining 5 did not. PDAI and ABSIS were not routinely 
used by any of the clinicians. Prior to the study day, a set of training clinical slides 
demonstrating the ODSS system, ABSIS and PDAI was circulated to all the 
clinicians.  On the study day, clinicians met with the Chief Investigator for a detailed 
discussion of each methodology, review of the clinical slide set and to familiarise 
themselves with the calibration of each system. All clinicians examined all of the 
patients once and 2 clinicians examined all of the patients twice (with a 2 hour 
interval to reduce recall). 
 
Patients 
Fifteen adult patients (aged 18-80) with a confirmed diagnosis of predominantly oral 
mucosal PV (based on clinical findings, histopathology and positive direct 
immunofluorescence as previously described13) participated in the study. Patients 
were recruited consecutively from the Oral Medicine department. The visit replaced 
one of their routine follow-up appointments. Thirteen had mild to moderately severe 
oral disease; one was in clinical remission and one had severe oral disease. All were 
on systemic treatment (9 mycophenolate mofetil, 4 azathioprine and 1 rituximab with 
or without prednisolone) at the time of the study. 
 
Oral Disease Severity Score (ODSS)  
The ODSS is a comprehensive oral scoring system previously validated for lichen 
planus (Fig. 1).8 It has additionally been used sequentially in PV and LP. 10, 11 It 
divides the mouth into 17 sites weighted according to area of possible involvement 
and allocated a site score of 0-2. The sites include the outer / inner lips, left and right 
buccal mucosa 6 gingival segments, hard palate (left / right or both), soft palate (left / 
right or both), dorsum tongue (left / right or both), left ventral tongue, right ventral 
tongue, floor of mouth (left / right or both) and oropharynx.  Individual sites (or units 
of a site) are then allocated an activity score (0-3), reflecting mild inflammation 
(minimal erythema or a white ‘healing’ mucosa) = 1 (Fig. 2a); moderate inflammation 
(marked erythema but no ulceration) = 2 (Fig. 2b) and ulceration = 3 (Fig. 2c). 
Additionally a subjective assessment of the patient’s oral pain in the preceding week 
is included (verbal rating scale  of 0-10). The theoretical maximum total score is 106; 
however greater than 95% of patients would be expected to have scores in the range 
from 0 to 60 representing a clinical range from remission to severe disease. 
 
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) 
The ABSIS is designed to assess the extent and quality of skin and oral lesions (Fig. 
3). It has a total score of 206 (150 points for skin involvement, 11 for oral and 45 for 
subjective discomfort). For the present study we used only the oral mucosal part of 
the system. This evaluates 11 distinct anatomical sites. The presence or absence of 
any lesion (blister / erosion) is allocated a score of 0 or 1 with a total score of 11. The 
second part of the score is for severity of symptoms which details the discomfort 
whilst eating and drinking maximum score 45. A higher score represents more severe 
disease.4 
 
Pemphigus Disease Area Index (PDAI)  
The PDAI was developed by the International Pemphigus Committee to capture the 
spectrum of PV (Fig. 3).5, 6 The skin, scalp and mucosa are scored separately for both 
the number of lesions (ulcers or erosions) present and evidence of damage (skin and 
scalp). There is no score for erythema / damage in the oral mucosa. The total possible 
score is 250 (120 for skin, 10 for scalp and 120 for mucosal site activity).5 For the 
purpose of this study only oral mucosal surfaces were scored with a possible total of 
90 (excluding the eyes, nose and anogenital areas). 
 
Physician’s Global Assessment (PGA)  
The Physician Global Assessment is a simple scoring method for inflammatory skin 
disease (Fig. 5). It is a ten-point analogue scale from 0 (perfect health) to 10 (worst 
condition imaginable). The clinicians score the participants on a global impression of 
their disease. This score method has been validated in a number of diseases including 
psoriasis and eczema.6, 12, 14 
 
Time for scoring methodology completion 
An independent assistant scored the time (seconds) taken by each clinician to obtain a 
disease severity score for each method using a stopwatch. 
 
Statistical Methods 
Inter-observer reliability was undertaken with 10 observers (clinicians) scoring all 
patients with each of the four scoring methodologies. A sample size of 15 subjects 
was required to achieve intra-class correlations (ICC) of 0.77 for the inter-observer 
reliability. 
Intra-observer reliability was tested with 2 replications per subject (as per test-retest) 
with a minimum of 2 hours between scores to minimise the risk of recall. Since the 
involvement was more onerous (burden, time or money resources, etc.) for the rater 
than for the subject, taking rater as fixed in the factorial design was more efficient. 
We fixed the number of raters to 2 and found the sample size required in terms of the 
number of subjects (which are assumed to be a random sample from the population of 
subjects). With both raters performing 2 replications in each methodology in all the 
subjects, a total of 15 subjects provides 80% power to detect an ICC difference of 
0.50 (relative to a null value of 0.20). Anticipating an ICC of 0.85, 15 subjects with 2 
replications will yield a width of 0.30 in the 95% confidence interval. 
 
Multilevel models were used to quantify intra- and inter-observer reliabilities of the 
continuous measures. Assessment for the level of agreement in terms of the intra-class 
correlation coefficients for ordinal or continuous measures followed well established 
benchmark limits (Fleiss and Altman’s benchmark scales).15, 16 Landis-Koch’s 
benchmark values were followed when Kappa coefficients were used for categorical 
outcomes. In all cases, for more rigour, in addition to the point estimate, we took into 
account the lower bound of the 95% confidence interval.17 Convergent validity was 
calculated using the Spearman rank correlation coefficient. 
 
RESULTS 
Fifteen patients (f11:m4) with confirmed PV were included. Their mean (SD) age was 
56±14.2 years (range 23-77).  
 
The distribution of scores:  
ODSS:  
The mean (SD) total ODSS score was 22.3±12.8, (range 0-68); median [IQR] 22 
[12.75-29], reflecting mild to moderately severe disease in 13/15. In one patient no 
lesions were identified (score 0), while another with very severe disease had a score 
of 68. 
PDAI:  
The mean PDAI activity score for oral mucosa was 14.6±7.7, (range 0-42); median 
14.6 [11.0-16.5]. 
ABSIS:  
The mean total score was 12.5±1.1, (range 0-43); median 11.7 [5.4-17.5]. The mean 
score for oral involvement; was 3.6 ±2.3; median 4 [2-5]. For disease severity the 
mean was 8.4±7.0; median 8 [0.5-12.5].  
PGA:  
The mean score was 6.1±0.9, (range 0-9); median 3 [1-8]. 
 
Reliability 
Test-retest reliability (Table 1) 
Intra-observer agreement between initial scoring and re-scoring of the same subjects 
demonstrated an intra-class correlation coefficient (ICC) for each of the two 
examiners of 0.96 and 0.97 for ODSS total, 0.95 and 0.97 ODSS site, 0.95 and 0.98 
ODSS activity and 0.9 and 0.97 for ODSS pain. As only oral mucosal sites were 
scored for the PDAI, the total PDAI reflects activity only with no damage score. The 
PDAI ICC was 0.82 and 0.99. The ABSIS total ICC was 0.45 and 0.72 with ABSIS 
involvement 0.9 and 0.94 and ABSIS severity 0.44 and 0.91. The ICC for PGA was 
0.64 and 0.99. 
 
Inter-observer reliability (Table 2) 
The ICC for the total ODSS score was 0.83 (0.71-0.94); ODSS site 0.69 (0.52-0.86), 
ODSS activity 0.83 (0.72-0.94), and ODSS pain 0.9 (0.84-0.97). The PDAI activity 
ICC was 0.79 (0.65-0.92). For ABSIS the ICC for total score was 0.71 (0.55-0.88); 
oral involvement 0.72 (0.57-0.83) and severity 0.67 (0.5-0.85). The PGA ICC was 0.7 
(0.54-0.87).  
 
Convergent Validity (Tables 3) 
The convergent validity between the PDAI activity (gold standard) and the other 
indices are detailed in Table 3. There was good convergent validity for all indices 
(ODSS total 0.70, ABSIS total 0.51 and PGA 0.77, p<0.0001). 
 
Time taken for completion of disease scoring methodologies  
The mean (SD) time to obtain a disease severity score for ODSS was 76 ±37; PDAI 
117±16 and ABSIS 75±19 seconds.  
DISCUSSION 
This study has shown that the ODSS is a valid method for assessment of disease 
severity for oral PV and has a higher inter- and intra-observer reliability than the 
previously validated methodologies PDAI, ABSIS and PGA.  
 
The patient sample used in this study reflects the reported sex and age distribution of 
PV with a broad range of oral disease severity (mild to severe) despite all being on 
systemic treatment.18 The mean and range of scores for ABSIS and PDAI were 
detailed by Rosenbach in their validation study and reflect a similar and potentially 
milder group of patients. 6  
 
In terms of reliability of the methodologies, the intra-observer scores were excellent, 
almost perfect (ICC>0.9) for all parameters for ODSS (0.95-0.97) for total score, 
PDAI (0.82-0.99) and for ABSIS total score (0.86-0.45). Intra-observer scores were 
given a benchmark value of good / substantial for PDAI activity and fair / moderate 
for total score for ABSIS. For PGA the benchmark value was good / substantial. 
Rosenbach’s data showed that for intra-observer reliability, using the test-retest 
method (2 replications), the ICC was 0.98 (0.97-1.0) for PDAI mucous membrane 
activity and for ABSIS oral involvement was 0.99 (0.97-1.0). ABSIS subjective 
discomfort was not calculable due to a lack of variability among subjects. Our data 
has shown better intra-observer scores for ODSS than the other methods examined.  
 
For inter-observer reliabilities the ODSS total score was ICC 0.83. Benchmarking 
values were very good or excellent for total score, activity and pain. For PDAI 
activity the ICC was 0.79 (very good); for ABSIS total score ICC was 0.71 (good / 
substantial) and for PGA 0.7 (good / substantial). Rosenbach reported an ICC of 0.84 
for PDAI; 0.85 for extent of mucosal disease with ABSIS, and 0.89 for subjective 
involvement. In our study the ODSS was more reliable among the scoring clinicians 
than the three other methods.  
 
The average time taken for clinicians to complete each of the scoring tools was less 
than 2 minutes; the longest completion time being PDAI. The time difference for 
completion of both the PDAI and ABSIS may in part be due to a lack of familiarity 
with the scoring systems as the clinicians did not routinely use either system 
nevertheless, the total time for all three was considered acceptable in a routine clinic. 
Furthermore, there was no significant difference in the mean time taken by clinicians 
scoring the ODSS clinically for the first time compared with those familiar with the 
system thus lack of familiarity should not have significantly influenced these data.  
 
In terms of convergent validity using PDAI as the previous ‘gold standard’, ODSS 
total score demonstrated good correlation with the PDAI activity score (correlation 
coefficient 0.7 p <0.0001).  
 
There are some limitations to the study. A valid outcome measure for PV should 
ideally be reliable, discriminatory, sensitive, accurate, feasible, close to a gold 
standard and have excellent external validity.19, 20 Potentially scores at the lower end 
of the spectrum for all methodologies might reduce the sensitivity and reproducibility 
of each scoring system. However, the fact that ODSS details more oral sites than 
either ABSIS or  PDAI, has a higher maximum score and combines both a semi-
quantitative score (site) with a qualitative score (activity) permits detailed 
differentiation between patients. Ideally the cohort would have included untreated 
severe patients but this would have necessitated withholding treatment. Secondly, the 
scoring instruments compared here looked only at the oral mucosal lesions and 
therefore would need to be undertaken alongside a skin and other mucosal site score. 
Thirdly intra-observer reliability was tested with a minimum 2-hour interval. This 
interval may allow recall bias and ideally this would be longer but more than a day or 
two might be associated with changes in disease activity. Furthermore patients would 
need to reattend which adds an impractical level of complexity to the study.  
 
In terms of external validity, the sample of patients included would ideally be 
randomly selected from a large cohort. Our sample was selected consecutively from 
those under current follow-up, with predominantly active disease and who were able 
to attend on the study day. We did not exclude any patient over and above those 
constraints. Clinicians with an interest in the field of immunobullous disease were 
invited and again were not randomly selected. The intra-observer reliability may have 
been improved by increasing the replications including those familiar and unfamiliar 
with the scoring methodologies. However using experienced clinicians in scoring 
methodologies is likely to have had a positive effect on all indices. Furthermore, this 
provided more data as there were a further 30 scores to analyse than just a further 10 
if each observer had just rescored one patient. Finally, sequential use of ODSS in case 
reports and a small case series has demonstrated efficacy of treatment in recalcitrant 
PV and LP. It now needs to be tested sequentially alongside PDAI and ABSIS to 
demonstrate sensitivity to change in disease activity and response to treatment in this 
cohort. 10, 11, 21 
 
We asked clinicians to comment on their experiences of each method. They all 
reported the ODSS to be the easiest method to use and felt that it more accurately and 
objectively recorded the extent of oral disease in PV. All would consider 
incorporating it into their routine assessment. The PDAI was considered to have 
potential for variable interpretation of the clinical features. The necessity of a lesion 
to be a blister or erosion precluded those lesions that were almost healed. It was also 
difficult to know how to score the number of lesions if confluent on the gingiva and 
including a few teeth amounting to <2cm, or if patchy and multiple. The ABSIS score 
was much easier to reflect severity, though it also required lesions to be blisters or 
erosions, thereby losing some sensitivity in white / healing areas. It had a substantial 
subjective component requiring the patient to report symptoms with foods and the 
reply sometimes depended upon how the questions were put to the patient. The 
system seemed weighted too strongly on this subjective component, which was not 
felt to allow for accurate recording of clinical severity. Finally the PGA, while simple, 
was felt to offer little information regarding the objective oral involvement of PV and 
potentially would be less valuable for sequential monitoring of disease. 
 
The ODSS has been used in a sequential study of 23 patients and demonstrated a 
positive association between oral disease activity and salivary antibodies to Dsg3.21 
ODSS has also previously been used to demonstrate cumulative efficacy to rituximab 
in patient with recalcitrant oral pemphigus where serial serum IgG Dsg3 titres 
followed clinical scores over several years follow up.11 In a cross-sectional study of 
PV patients comparing the inter-rater validity of PDAI, the Pemphigus Vulgaris 
Activity Score and ABSIS together with convergent validity according to anti-Dsg 
values, both inter-rater reliability and convergent validity were highest with PDAI.22 
In analysis of sequential serum samples from PV patients, the anti-Dsg3 indices 
showed a correlation with PDAI scores,23 while in a further study no correlation was 
found with either PDAI or ABSIS.24 Among predominantly mucosal PV patients, 
there was no correlation between either serum or salivary anti-Dsg1 or 3 antibodies 
and the total objective component of ABSIS, however serum anti-Dsg1 did correlate 
with cutaneous ABSIS.25 
 
As PV is a rare disease, establishing optimal therapeutic regimens has been very 
difficult. Multicentre collaborative trials are therefore essential.20 However; the lack 
of a universally accepted outcome measure has been highlighted in a recent 
systematic review.1 The PDAI is considered to be the optimal method for multisite 
disease in use to date. While patients with PV may initially have both mucosal and 
cutaneous lesions, many are left with pure oral disease, which is often severe and 
debilitating. We propose that a more sensitive method of assessing oral PV needs to 
be in place for these cases. The ODSS was first developed and published for use in LP 
and its use extended as part of a strategy of developing disease severity scores for a 
number of oral mucosal diseases.8, 28, 29, 30 It incorporates both objective measures of 
disease activity and severity as well as including patient subjective data allowing for a 
comprehensive appraisal of mucosal disease.8 The ODSS has been used in our 
department for more than 10 years and has been externally evaluated for use in MMP 
and has shown efficacy of treatment in PV and LP. 9, 10, 11 
 
In this study ODSS has been shown to be a reliable and reproducible tool for 
recording oral PV disease activity with inter- and intra-rater reliability at least as good 
as PDAI for oral lesions. It is simple to use and facilitates detailed recording of both 
the site and the severity of lesions including those that are healing. We propose that 
this scoring tool would be a useful supplement for future multicentre studies as well 
as recording sequential disease activity in the clinic. We are currently evaluating data 
on sequential scores using all 4 methods over a 1 year follow up to clarify which is 
the most sensitive to subtle changes in disease activity. 
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Table 1. Within observer (intra-observer) reliability data for each scoring 
methodology. *Assessment for the level of agreement in terms of the intra-class 
correlation coefficients followed Fleiss and Altman’s benchmark scales.16, 17 
ICC= intra-class correlations  
 
 Observer 1 
ICC (95% CI) 
Observer 2 ICC 
(95% CI) 
P-value Overall 
benchmark 
values* 
ODSS Site 0.95 
(0.86-1.00) 
0.97 
(0.94-1.00) 
0.36 Excellent 
ODSS Activity 0.98 
(0.95-1.00) 
0.95 
(0.91-1.00) 
0.61 Excellent 
ODSS Pain 0.97 
(0.97-1.00) 
0.90 
(0.80-0.99) 
0.43 Excellent 
ODSS Total 0.97 
(0.95-1.00) 
0.96 
(0.92-1.00) 
0.53 Excellent 
ABSIS 
Involvement 
0.94 
(0.89-1.00) 
0.90 
(0.80-1.00) 
0.83 Excellent 
ABSIS Severity 0.91 
(0.82-1.00) 
0.44 
(0.03-0.86) 
0.16 Fair / 
moderate 
ABSIS Total 0.86 
(0.72-0.99) 
0.45 
(0.04-0.86) 
0.46 Fair / 
moderate 
PDAI Activity 0.99 
(0.99-1.00) 
0.82 
(0.65-0.99) 
0.82 Good / 
substantial 
PGA 0.99 
(0.97-1.00) 
0.64 
(0.34-0.95) 
0.80 Good / 
substantial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Scores and Inter-observer reliability for each of four disease severity scoring 
systems, and individual components of ODSS. *Assessment for the level of 
agreement in terms of the intra-class correlation coefficients followed Fleiss and 
Altman’s benchmark scales.16, 17   
ICC= intra-class correlations 
IQR= interquartile range 
 
 
 Range Median (IQR) 
Mean±SD 
Inter-observer 
ICC 
(95% CI) 
Overall 
benchmark 
values* 
ODSS Site 
 
0-16 7 (4-10) 
7±3.84 
0.69 
(0.52-0.86) 
Good/Substantial 
ODSS Activity 0-48 11 (6-17) 
12.63±9.58 
0.83 
(0.72-0.94) 
Very good 
ODSS Pain 
 
0-6 3 (2-4) 
2.78±1.37 
0.9 
(0.84-0.97) 
Excellent 
ODSS Total 
(0-106) 
0-68 22 (12.75-29) 
22.3±12.8 
0.83 
(0.71-0.94) 
Very good 
ABSIS 
Involvement 
0-10 4 (2-5) 
3.65±2.3 
0.72 
(0.57-0.83) 
Good/Substantial 
ABSIS Severity 0-29.5 8 (0.5-12.5) 
8.41±7.01 
0.67 
(0.50-0.85) 
Moderate 
ABSIS Total 
(0-56) 
0-43 11.75 (5.4-17.5) 
12.5±1.1 
0.71 
(0.55-0.88) 
Good/Substantial 
PDAI Activity 
(0-90) 
0-42 13 (11.0-16.5) 
14.6±7.7 
0.79 
(0.65-0.92) 
Very good 
PGA 
(0-10) 
0-9 3 (1-8) 
6.1±0.9 
0.70 
(0.54-0.87) 
Good/Substantial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Disease Severity scoring systems: convergent validity of ODSS, ABSIS and 
PGA with PDAI Activity (n=15).  *Spearman rank correlation coefficient 
 
Scoring method Correlation Coefficient* P-value 
ODSS Total 0.70 <0.0001 
ABSIS Total 0.51 <0.0001 
PGA 0.77 <0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Guy’s Oral Disease Severity Score (ODSS) 
 
Figure 2a. Hard palate showing bilateral whitening of the mucosa indicating mild 
activity (site score= 2, activity 1+1=2) 
 
Figure 2b. Right buccal mucosa showing <50% affected with erythema and 
whitening but no frank ulceration (site score= 1, activity =2)  
 
Figure 2c. Right buccal mucosa demonstrating areas of ulceration affecting <50% 
surface area (site score=1, activity=3) 
 
Figure 3. Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) 
 
Figure 4. Pemphigus Disease Area Index (PDAI) 
 
Figure 5. Physician’s Global Assessment (PGA) 







